

INTERLEUKIN-6
MEAN CHANGE FROM BASELINE (pg/mL)
40
30
20
10
0
-10
BASELINE
2
4
6
8
10
12
WEEKS OF TREATMENT
10 mg
2.5 mg
PLACEBO
BASELINE MEAN = 15.64
BASELINE MEAN = 24.23
BASELINE MEAN = 10.08

FIG. 1



PROSTATE SPECIFIC ANTIGEN
MEAN CHANGE FROM BASELINE
165
145
125
105
85
65
45
25
5
-15
0
2
4
6
8
10
12
WEEK
ABT-627 10 mg
ABT-627 2.5 mg
PLACEBO

FIG.2



VAS PAIN ASSESSMENT
2.5 mg
PLACEBO
10 mg
CHANGE IN VAS SCORE
(Scale Range 1–10)
1
0.5
0
−0.5
−1
−1.5
−2
−2.5
−3
0
2
4
6
8
10
12
WEEKS
OPIOID ANALGESIC USE*
MEAN CHANGE
FROM BASELINE
400
300
200
100
0
−100
−200
−300
−400
* MORPHINE EQUIVALENTS (mg)

FIG.3



SERUM CROSSLINKED CARBOXYTERMINAL TELOPEPTIDE
MEAN CHANGE FROM BASELINE (MCG/L)
12
10
8
6
4
2
0
-2
BASELINE
2
4
6
8
10
12
WEEKS OF TREATMENT
10 mg
2.5 mg
PLACEBO
BASELINE MEAN = 9.6
BASELINE MEAN = 9.8
BASELINE MEAN = 11.9

FIG.4



BONE ALKALINE PHOSPHATASE
MEAN CHANGE FROM BASELINE (U/L)
150
100
50
0
-50
BASELINE
2
4
6
8
10
12
WEEKS OF TREATMENT
10 mg
2.5 mg
PLACEBO
BASELINE MEAN = 102
BASELINE MEAN = 137
BASELINE MEAN = 149

FIG.5



BONE SCAN INDEX
PBO N=24
2.5 mg N=23
10 mg N=32
BASELINE MEAN
8.18 9.34 7.97
TOTAL
4.25 5.24 4.92
AXIAL
3.93 4.10 3.05
APPENDICULAR
MEAN CHANGE FROM BASELINE BSI
5
4
3
2
1
0
BSI REPRESENTS % OF SKELETAL INVOLVEMENT.
TOTAL SKELETON (176.70)
* FOR SUBJECTS WHERE BOTH BASELINE AND FINAL SCANS WERE AVAILABLE.

FIG.6



ACID PHOSPHATASE
MEAN CHANGE FROM BASELINE (IU/L)
60
40
20
0
-20
BASELINE
2
4
6
8
10
12
WEEKS OF TREATMENT
10 mg
2.5 mg
PLACEBO
BASELINE MEAN = 42.8
BASELINE MEAN = 23.7
BASELINE MEAN = 76.2

FIG.7